Criteria for interpretation of agar diffusion susceptibility tests of norfloxacin performed by the ICS method

Bauer, A. W., Kirby, W. M. M., Sherris, J. C., Turck, M.: Antibiotic susceptibility testing by a standardized single disk method. American Journal of Clinical Pathology 1966, 45: 493–496.

Ericsson, H. M., Sherris, J. C.: Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathologica et Microbiologica Scandinavica 1971, Supplement 217: 1–90.

Shungu, D. L., Weinberg, E., Gadebusch, H. H.: Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrobial Agents and Chemotherapy 1983, 23: 256–260.

Woods, S. J., Shadomy, S.: Disk diffusion susceptibility tests with norfloxacin (MK-0366, AM-715): confirmation of proposed interpretive criteria. European Journal of Clinical Microbiology 1983, 2: 242–244.

Boppana, V. K., Swanson, B. N.: Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy 1982, 21: 808–810.

NCCLS Proposed Standard: PSM-7: Standard methods for dilution antimicrobial susceptibility tests for bacteria which grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA, 1980, p. 1–31.

DIN 58940, Teil 4, Beiblatt 2: Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika. Bewertungsstufen der minimalen Hemmkonzentration. Liste der durchschnittlichen Tagesdosierungen. Beuth-Verlag, Berlin, 1982.

Metzler, C. M., DeHaan, R. M.: Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. Journal of Infectious Diseases 1974, 130: 588–594.